GT Biopharma Restates Q2 2025 Financials, Revealing $28.7M Liability & Negative Equity

summarizeSummary

GT Biopharma restated its Q2 2025 financials, revealing a $28.7 million Greenshoe Rights liability, which caused stockholders' equity to turn significantly negative and dramatically increased net loss, highlighting severe financial distress and renewed Nasdaq delisting risk.

check_boxKey Events

• Material Financial Restatement

  The company restated its Quarterly Report for June 30, 2025, to correct a material error in classifying $28.7 million in 'Greenshoe Rights' as a liability, which were previously unrecognized.

• Significant Financial Deterioration

  The restatement caused total liabilities to increase by $28.7 million and swung stockholders' equity from a positive $2.86 million to a negative $25.88 million as of June 30, 2025. Net loss for the quarter increased from $(1.43) million to $(30.17) million.

• Material Weakness in Internal Controls

  Management concluded that disclosure controls and procedures were ineffective as of June 30, 2025, due to errors in accounting for complex financial transactions, constituting a material weakness.

• Renewed Nasdaq Delisting Risk

  The restated negative stockholders' equity of $(25.88) million likely puts the company back out of compliance with Nasdaq's minimum listing requirement of $2.5 million, despite a prior notification of regaining compliance.

auto_awesomeAnalysis

GT Biopharma, Inc. filed an amended Quarterly Report (10-Q/A) to restate its financial statements for the quarter ended June 30, 2025. The restatement corrects a material error related to the classification of $28.7 million in 'Greenshoe Rights' as a liability, which were previously not recognized. This reclassification significantly impacts the company's financial position, increasing total liabilities by $28.7 million and swinging stockholders' equity from a previously reported positive $2.86 million to a negative $25.88 million. The net loss for the quarter also dramatically increased from $(1.43) million to $(30.17) million. This substantial financial deterioration, coupled with the disclosure of a material weakness in internal controls, raises severe concerns about the company's financial health and its ability to maintain Nasdaq listing compliance, despite a prior notification of regaining compliance. Subsequent events also indicate further dilutive activities.